J. Goldman & Co’s ProQR Therapeutics PRQR Stock Holding History

J. Goldman & Co’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-102,120	Closed	-$818K	–	428
2021 Q4	$818K	Sell	102,120 -94,380	-48%	-$719K	0.05%	268
2021 Q3	$1.65M	Buy	+196,500	New	+$1.28M	0.08%	207
2018 Q3	–	Sell	-222,284	Closed	-$1.62M	–	366
2018 Q2	$1.62M	Buy	+222,284	New	+$1.12M	0.08%	220

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

J. Goldman & Co's PRQR Position: Q1 2022 in Review

J. Goldman & Co sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 102,120 shares — an estimated $818K sold.

J. Goldman & Co first reported a position in PRQR in Q2 2018 and held it in 3 quarters. The position peaked at $1.65M in Q3 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

J. Goldman & Co reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
J. Goldman & Co sold 102,120 ProQR Therapeutics shares in Q1 2022, an estimated $818K.
J. Goldman & Co first reported a position in ProQR Therapeutics in Q2 2018 and held it in 3 quarters.
J. Goldman & Co's ProQR Therapeutics position peaked at $1.65M in Q3 2021.
58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on J. Goldman & Co's 13F filing for Q1 2022, filed 16 May 2022.